Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02099864 · ClinicalTrials.gov registry record · Phase 2

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

A Phase 2 study of Castration-Resistant Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by OHSU Knight Cancer Institute.

Completed
Registry status
Phase 2
Development phase
36
Enrollment target
2
Study locations

NCT02099864 is a Phase 2 study of Castration-Resistant Prostate Carcinoma and Recurrent Prostate Carcinoma that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 36 participants, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02099864, a Phase 2 study of Castration-Resistant Prostate Carcinoma and Recurrent Prostate Carcinoma, has completed, sponsored by OHSU Knight Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
36 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body. Studying samples of tissue and blood in the laboratory from patients with prostate cancer may help doctors better understand castration-resistant prostate cancer. It may also help doctors make improvements in prostate cancer treatment.

Conditions Studied

Castration-Resistant Prostate Carcinoma Recurrent Prostate Carcinoma Metastatic Prostate Adenocarcinoma Metastatic Malignant Neoplasm in the Bone Stage IV Prostate Adenocarcinoma AJCC v7 Stage III Prostate Adenocarcinoma AJCC v7 Metastatic Malignant Neoplasm in the Soft Tissues

Interventions

  • DRUG Enzalutamide

Study Locations (2)

California

  • UCSF Medical Center-Mount Zion - San Francisco

Oregon

  • OHSU Knight Cancer Institute - Portland

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2014-02-05
Est. Completion 2024-07-08
Phase Phase 2

Sponsor

OHSU Knight Cancer Institute

211 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02099864

The ClinicalTrials.gov registry entry for NCT02099864 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (53% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Enzalutamide is the first listed.

NCT02099864 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Oregon.

Frequently Asked Questions

What is clinical trial NCT02099864 about?

NCT02099864 is a clinical study titled "Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy". This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body....

What is the current status of trial NCT02099864?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-02-05. Estimated completion is 2024-07-08.

What conditions does trial NCT02099864 study?

This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Malignant Neoplasm in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7.

What interventions are being tested in trial NCT02099864?

The interventions under investigation include: Enzalutamide (DRUG).

Who is sponsoring clinical trial NCT02099864?

This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02099864 being conducted?

This trial has 2 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Castration-Resistant Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Castration-Resistant Prostate Carcinoma

All registered trials for this condition

Recurrent Prostate Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.